General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Foundations

Philanthropy remains indispensable in reaching people who live in abject poverty with significant unmet medical needs.

One of our largest philanthropic efforts focuses on controlling and eliminating leprosy. Since 2000, Novartis has worked with the World Health Organization to provide free treatments to people with leprosy, helping to treat more than 5 million people. In 2012, we agreed to extend donations of multidrug therapy through 2020, and we expect eventually to reach about 850 000 people.

The Novartis Foundation for Sustainable Development works to create sustainable health service models and improve access to healthcare for those most in need, leveraging its on-the-ground experience and partnerships to bring private sector solutions to public health problems. The foundation also explores new interventions to bring the world closer to the eventual goal of leprosy and malaria elimination.

Alcon Foundation

Through The Alcon Foundation and corporate giving efforts, we serve the global community by supporting efforts to make quality, sustainable eye care more accessible abroad and at home. For example, Alcon supports more than 800 medical missions and numerous partnerships with non-profit organizations each year to raise awareness of eye health education, train local physicians to perform state-of-the-art surgery, and bring much-needed eye care treatments and services to places where it doesn’t yet exist.

Novartis Venture Fund

With an initial venture capital of CHF 100 million, the Venture Fund supports new business projects that show exemplary entrepreneurial and innovative spirit in future-oriented areas, especially life sciences and new technologies.

Contact:
Martina Blank
Office Manager
Novartis Venture Funds
Novartis International AG, Forum 1- 3.73
P.O. Box, CH-4002 Basel, Switzerland
+41 61 324 32 67
+41 61 324 86 79

www.venturefund.novartis.com

Novartis US Foundation

The Novartis US Foundation was established in 1997 as part of Novartis Corporation's commitment to social investment in the US. Its primary purpose is to support efforts among communities, businesses, and nonprofit organizations on a range of social, health, and education issues related to healthcare.

Novartis Jubilee Foundation

The Novartis Jubilee Foundation, formerly the Ciba-Geigy Jubilee Foundation, sponsors and encourages young scientists in Switzerland. Through its support for research projects, it contributes to the preservation and strengthening of Switzerland as a "research laboratory."

Contact:
Novartis Jubilee Foundation
Fabrikstrasse 6-2­.­22­
Postfach
CH-4002 Basel
+41 61 324 90 88

www.jubilaeumsstiftung.novartis.com